US2016113934A1PendingUtilityA1

Preservative free bimatoprost and timolol solutions

41
Assignee: ALLERGAN INCPriority: Jul 29, 2010Filed: Jun 8, 2015Published: Apr 28, 2016
Est. expiryJul 29, 2030(~4 yrs left)· nominal 20-yr term from priority
Inventors:Sukhon LikitlersuangAjay ParasharChetan P. PujaraWilliam F. Kelly
A61P 43/00A61P 27/02A61P 27/06A61K 31/165A61K 9/08A61K 31/5575A61K 31/5377A61K 2121/00A61K 47/12A61K 9/0048A61K 2300/00A61K 47/02A61K 45/06A61K 31/498
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intra-ocular pressure and treatment of glaucoma.

Claims

exact text as granted — not AI-modified
1 ) A preservative free bimatoprost and timolol composition for lowering intraocular pressure in a patient comprising the following formulation: about 0.03% w/v bimatoprost; about 0.5% timolol; about 0.268% w/v Sodium Phosphate Dibasic Heptahydrate; about 0.014% Citric Acid Monohydrate; about 0.68% sodium chloride; water and having a pH of about 7.3. 
     
     
         2 ) The preservative free bimatoprost and timolol composition of  claim 1  for lowering intraocular pressure in a patient comprising the following formulation: 0.03% w/v bimatoprost; 0.5% timolol; 0.268% w/v Sodium Phosphate Dibasic Heptahydrate; 0.014% Citric Acid Monohydrate; about 0.68% sodium chloride; water and having a pH of about 7.3. 
     
     
         3 ) The preservative free bimatoprost and timolol solution of  claim 2  wherein the timolol is timolol maleate at 0.68% w/v. 
     
     
         4 ) A composition as described in Table 1. 
     
     
         5 ) The bimatoprost and timolol composition of  claim 1  wherein the composition is a solution and is useful for treating glaucoma. 
     
     
         6 ) The bimatoprost and timolol composition of  claim 1  wherein the composition is contained in a unit dose kit form. 
     
     
         7 ) The bimatoprost and timolol composition of  claim 1  wherein the composition is applied once a day to each eye. 
     
     
         8 ) The bimatoprost and timolol composition of  claim 1  wherein the composition is applied twice a day to each eye. 
     
     
         9 ) The bimatoprost and timolol composition of  claim 1  wherein the composition has greater bioavailability of bimatoprost and timolol in the eye of the patient with fewer side-effects than bimatoprost and timolol preserved with benzalkonium chloride. 
     
     
         10 ) The bimatoprost and timolol composition of  claim 1  wherein the composition is a solution contained in a unit dose vial.

Join the waitlist — get patent alerts

Track US2016113934A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.